Incidence of Heart Failure Among Hispanic/Latino Individuals in the United States: Insights from the Hispanic Community Health Study/Study of Latinos
Abstract Body (Do not enter title and authors here): Introduction: Hispanic/Latino individuals are known to have higher traditional cardiovascular disease (CVD) risk factors compared to non-Hispanic Whites and Asians. However, inconsistencies and variability exist regarding the incidence of heart failure (HF) among Hispanics compared to other race/ethnic groups. We examined the incidence of HF in participants enrolled in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
Methods: The baseline HCHS/SOL population consisted of 16,415 participants enrolled between 2008 - 2011 and followed up for incident HF events through 2015 (mean follow up period of 5.8 years). A total of 1000 participants with pre-existing HF at baseline, or with missing information/response for baseline HF, socio-economic status (SES), CVD risk factors, and medication use were excluded. Outcome was ascertained via self-report of events at annual follow-up interviews. HF events were adjudicated by trained physicians who reviewed hospital records. HCHS/SOL participants were stratified into seven Hispanic/Latino heritage groups: Mexican, Dominican, Cuban, Puerto Rican, South or Central American, as well as more than one/other. Cox-proportional hazard regression models were used to calculate HRs for incident HF with Mexican Americans as the reference group and controlling for SES, CVD risk factors, and medication use.
Results: A total of 15,415 participants [mean age 41 years, 52.2% Female) were included and 114 HF events (69 Males and 45 Females) were identified after 89,751 person-years follow up. The HF incidence rate was 94.6 per 100,000 persons-years. Hispanic/Latino individuals of Cuban background had the highest HF incidence rate (131.4 per 100,000 person-years) while those from Central American backgrounds had the lowest (42.8 per 100,000 person-years). Hispanic/Latino individuals of Cuban background [HR: 1.471 (95% C.I: 0.397,5.447)] and Dominican background [HR: 0.509 (95% C.I: 0.075, 3.429)] had the highest and lowest adjusted HR of incident HF compared to those of Mexican background.
Conclusion: Among different Hispanic/Latino heritage groups, the incidence rate for HF was highest among those with Cuban background and lowest among those with a Central American background.
Nriagu, Bede
( New York Medical Coll-Metropolitan
, New York
, New York
, United States
)
Hurwitz, Barry
( UNIVERSITY OF MIAMI
, Miami
, Florida
, United States
)
Chavez, Patricia
( Yale New Haven Health
, Greenwich
, Connecticut
, United States
)
Aviles-santa, Larissa
( NHLBI
, Bethesda
, Maryland
, United States
)
Solomon, Scott
( Brigham and Women's Hospital
, Boston
, Massachusetts
, United States
)
Cheng, Susan
( Cedars-Sinai Medical Center
, Los Aeles
, California
, United States
)
Shook-sa, Bonnie
( University of North Carolina
, Chapel Hill
, North Carolina
, United States
)
Cai, Jianwen
( UNC Chapel Hill
, Chapel Hill
, North Carolina
, United States
)
Gallo, Linda
( San Diego State University
, Chula Vista
, California
, United States
)
Rodriguez, Carlos
( Albert Einstein School of Medicine
, Bronx
, New York
, United States
)
Duran Luciano, Priscilla
( Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Pandey, Ambarish
( UTSW MEDICAL CENTER
, Dallas
, Texas
, United States
)
Daviglus, Martha
( UNIVERSITY ILLINOIS CHICAGO
, Chicago
, Illinois
, United States
)
Talavera, Gregory
( SAN DIEGO STATE UNIVERSITY
, Chula Vista
, California
, United States
)
Kaplan, Robert
( Albert Einstein College of Medicine
, Bronx
, New York
, United States
)
Shah, Sanjiv
( NORTHWESTERN UNIVERSITY
, Chicago
, Illinois
, United States
)
Allison, Matthew
( University of California San Diego
, La Jolla
, California
, United States
)
Kizer, Jorge
( San Francisco VA
, San Francisco
, California
, United States
)
Author Disclosures:
Bede Nriagu:DO NOT have relevant financial relationships
| Barry Hurwitz:DO NOT have relevant financial relationships
| Patricia Chavez:No Answer
| Larissa Aviles-Santa:DO NOT have relevant financial relationships
| Scott Solomon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now)
; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo:Active (exists now)
| Susan Cheng:DO have relevant financial relationships
;
Consultant:UCB:Active (exists now)
| Bonnie Shook-Sa:DO NOT have relevant financial relationships
| Jianwen Cai:DO NOT have relevant financial relationships
| Linda Gallo:DO NOT have relevant financial relationships
| Carlos Rodriguez:DO NOT have relevant financial relationships
| Priscilla Duran Luciano:DO NOT have relevant financial relationships
| Ambarish Pandey:DO have relevant financial relationships
;
Consultant:Tricog:Active (exists now)
; Consultant:Lilly:Active (exists now)
; Consultant:Edwards Lifesciences:Active (exists now)
; Consultant:Semler:Active (exists now)
; Consultant:Science37:Active (exists now)
; Research Funding (PI or named investigator):SCPharma:Active (exists now)
; Advisor:Medtronic:Active (exists now)
; Advisor:Axon:Active (exists now)
; Advisor:Bayer:Active (exists now)
; Research Funding (PI or named investigator):Ultromics:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Consultant:Roche:Active (exists now)
| Martha Daviglus:DO NOT have relevant financial relationships
| Gregory Talavera:DO NOT have relevant financial relationships
| Robert Kaplan:No Answer
| Sanjiv Shah:DO have relevant financial relationships
;
Consultant:Bayer:Active (exists now)
; Consultant:Merck:Active (exists now)
; Consultant:Axon Therapies:Active (exists now)
; Consultant:Corvia :Active (exists now)
; Consultant:Boehringer-Ingelheim:Active (exists now)
; Consultant:Bristol-Myers Squibb:Active (exists now)
; Consultant:Ionis:Active (exists now)
; Consultant:Novartis:Active (exists now)
; Consultant:Tenax:Active (exists now)
; Consultant:Intellia:Active (exists now)
; Consultant:Rivus:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Consultant:Lilly:Active (exists now)
; Consultant:Pfizer:Active (exists now)
; Consultant:AstraZeneca:Active (exists now)
| Matthew Allison:DO NOT have relevant financial relationships
| JORGE KIZER:DO have relevant financial relationships
;
Individual Stocks/Stock Options:Abbott:Past (completed)
; Individual Stocks/Stock Options:Pfizer:Past (completed)
; Individual Stocks/Stock Options:Merck:Past (completed)
; Individual Stocks/Stock Options:Medtronic:Past (completed)
; Individual Stocks/Stock Options:Lilly:Past (completed)
; Individual Stocks/Stock Options:Johnson & Johnson:Past (completed)
; Individual Stocks/Stock Options:Bristol Myers Squibb:Past (completed)
; Individual Stocks/Stock Options:AbbVie:Past (completed)